Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation-Reference-Cited by-同舟云学术

Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation

Published:2023-02-21 Issue: Volume: Page:
ISSN:1530-7905
Container-title:Cardiovascular Toxicology
language:en
Short-container-title:Cardiovasc Toxicol

Author:

Jannuzzi Ayse Tarbin,Korkmaz Nalan Sümeyra,Gunaydin Akyildiz Aysenur,Arslan Eseryel Sema,Karademir Yilmaz Betul,Alpertunga Buket

Funder

Istanbul University Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Toxicology,Molecular Biology

Link

https://link.springer.com/content/pdf/10.1007/s12012-023-09785-7.pdf

Reference40 articles.

1. Wu, P., Oren, O., Gertz, M. A., & Yang, E. H. (2020). Proteasome inhibitor-related cardiotoxicity: Mechanisms, diagnosis, and management. Current Oncology Reports, 22(7), 1–14.

2. Shah, C., Bishnoi, R., Jain, A., Bejjanki, H., Xiong, S., Wang, Y., Zou, F., & Moreb, J. S. (2018). Cardiotoxicity associated with carfilzomib: Systematic review and meta-analysis. Leukemia & lymphoma, 59(11), 2557–2569.

3. Jouni, H., Aubry, M. C., Lacy, M. Q., Kumar, S. K., Frye, R. L., & Herrmann, J. (2017). Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. American Journal of Hematology, 92(2), 220–221.

4. Shirley, M. (2016). Ixazomib: First global approval. Drugs, 76(3), 405–411.

5. Ling, Y., Li, R., Zhong, J., Zhao, Y., & Chen, Z. (2022). Ixazomib-associated cardiovascular adverse events in multiple myeloma: A systematic review and meta-analysis. Drug and Chemical Toxicology, 45(4), 1443–1448.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms;Journal of Molecular and Cellular Cardiology;2024-09

2. Gastrointestinal toxicities of proteasome inhibitor therapy;Journal of Cancer Research and Clinical Oncology;2024-07-05

3. Design and Synthesis of Novel Anti-proliferative Formononetin Derivatives;Letters in Drug Design & Discovery;2024-03-04

4. Antineoplastic drugs inducing cardiac and vascular toxicity – An update;Vascular Pharmacology;2023-12